The Effect of Phosphodiesterase 5 Inhibitor on Biochemical Recurrence Following Radical Prostatectomy in Patients with Prostate Cancer
Vol. 16 No. 3 (2019),
17 June 2019
Purpose: Recently, controversy exists regarding the oncologic outcomes associated with the use of phosphodiesterase 5 inhibitor (PDE5i). Therefore, we attempted to verify the effect of PDE5i on biochemical recurrence (BCR) following radical prostatectomy (RP) in patients with prostate cancer (PCa).
Materials and Methods: From January 2011 to May 2016, 351 patients who had undergone bilateral neurovascular bundle saving and who were confirmed as having pT2N0M0 disease were included in the present study. We divided these patients into three groups: no PDE5i use, PDE5i use on demand , and PDE5i use for rehabilitation. We retrospectively analyzed the effect of PDE5i on BCR of PCa. Mean follow-up period was 34.4 months and mesurement of outcome was whether the patients developed BCR during regular follow-up.
Results: 25 (7.1%) patients showed BCR and univariate analysis found no significant differences in BCR between the three groups (5 (6.9%) in no PDE5i use, 8 (9.5%) in PDE5i use on demand, 12 (6.2%) in PDE5i use for rehabilitation). Multivariable analyses showed that treatment type was not a significant factor for BCR between the groups with no PDE5i use and PDE5i use (HR = 1.34 [0.49–3.70]; P = .573) and between the groups with on demand and rehabilitation use (HR = 1.37 [0.35–5.37]; P = .646). Kaplan-Meier survival curves show that there were no significant differences in PSA recurrence-free survival in three groups (P > .05).
Conclusion: Use of PDE5is was not associated with any adverse effects on BCR after RP in patients with PCa.
How to Cite
Siegel R, Ma JM, Zou ZH, Jemal A. Cancer Statistics, 2014. Ca-a Cancer Journal for Clinicians. 2014;64:9-29.
Pu YS, Chiang HS, Lin CC, Huang CY, Huang KH, Chen J. Changing trends of prostate cancer in Asia. Aging Male. 2004;7:120-32.
Jung KW, Won YJ, Kong HJ, Oh CM, Seo HG, Lee JS. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat. 2013;45:1-14.
Brock G, Nehra A, Lipshultz LI, et al. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol. 2003;170:1278-83.
Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368:436-45.
Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. New England Journal of Medicine. 2008;358:1250-61.
Mulhall JP. Defining and Reporting Erectile Function Outcomes After Radical Prostatectomy: Challenges and Misconceptions. Journal of Urology. 2009;181:462-71.
Walsh PC, Donker PJ. Impotence following radical prostatectomy: Insight into etiology and prevention (Reprinted from J Urol, vol 128, pg 492-497, 1982). Journal of Urology. 2002;167:1005-10.
Lowe G, Costabile RA. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. J Sex Med. 2012;9:265-70.
Salonia A, Burnett AL, Graefen M, et al. Prevention and management of postprostatectomy sexual dysfunctions part 2: recovery and preservation of erectile function, sexual desire, and orgasmic function. Eur Urol. 2012;62:273-86.
Gallina A, Bianchi M, Gandaglia G, et al. A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy. European Urology. 2015;68:750-3.
Jo JK, Kim K, Lee SE, Lee JK, Byun SS, Hong SK. Phosphodiesterase Type 5 Inhibitor Use Following Radical Prostatectomy is not Associated with an Increased Risk of Biochemical Recurrence. Annals of Surgical Oncology. 2016;23:1760-7.
Kim SJ, Kim JH, Chang HK, Kim KH. Let's rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy. J Exerc Rehabil. 2016;12:143-7.
Michl U, Molfenter F, Graefen M, et al. Use of Phosphodiesterase Type 5 Inhibitors May Adversely Impact Biochemical Recurrence after Radical Prostatectomy. Journal of Urology. 2015;193:479-83.
Rambhatla A, Kovanecz I, Ferrini M, Gonzalez-Cadavid NF, Rajfer J. Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical review. International Journal of Impotence Research. 2008;20:30-4.
Mydlo JH, Viterbo R, Crispen P. Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy. Bju International. 2005;95:843-6.
Ohebshalom M, Parker M, Guhring P, Mulhall JP. The efficacy of sildenafil citrate following radiation therapy for prostate cancer: Temporal considerations. Journal of Urology. 2005;174:258-62.
Schiff JD, Bar-Chama N, Cesaretti J, Stock R. Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function. Bju International. 2006;98:1255-8.
Teloken PE, Ohebshalom M, Mohideen N, Mulhall JP. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer. Journal of Urology. 2007;178:2521-5.
Zippe CD, Jhaveri FM, Klein EA, et al. Role of Viagra after radical prostatectomy. Urology. 2000;55:241-5.
Zippe CD, Kedia AW, Kedia K, Nelson DR, Agarwal A. Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology. 1998;52:963-6.
Raina R, Lakin MM, Agarwal A, et al. Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology. 2004;63:960-6.
Feng MI, Huang S, Kaptein J, Kaswick J, Aboseif S. Effect of sildenafil citrate on post-radical prostatectomy erectile dysfunction. Journal of Urology. 2000;164:1935-8.
Kim TH, Ha YS, Choi SH, et al. Factors predicting outcomes of penile rehabilitation with udenafil 50 mg following radical prostatectomy (vol 28, pg 25, 2015). International Journal of Impotence Research. 2016;28:80-.
Goluboff ET, Shabsigh A, Saidi JA, et al. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology. 1999;53:440-5.
Goluboff ET, Prager D, Rukstalis D, et al. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. J Urol. 2001;166:882-6.
Narayanan BA, Reddy BS, Bosland MC, et al. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence. Clin Cancer Res. 2007;13:5965-73.
Qian CN, Takahashi M, Kahnoski R, Teh BT. Effect of sildenafil citrate on an orthotopic prostate cancer growth and metastasis model. J Urol. 2003;170:994-7.
Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203:2691-702.
- Abstract Viewed: 383 times
- PDF/4263 Downloaded: 185 times